Therapeutic effect of Guluronat on disease severity in MS

Phase 2

Recruiting

• Conditions: Multiple Sclerosis.; Multiple Sclerosis

• Registration Number: IRCT2017042313739N8
• Lead Sponsor: Vice chancellor for Research, Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Inclusion Criteria: diagnosed with multiple sclerosis who were injecting different forms interferon,beta (interferon beta, 1a, interferon beta, 1b) at least 6 months before the trial. Also, the patients have been chosen by neurologist among active patients on the basis of disease activity who have had at least one relapsing period during 6month or have active lesions in their MRI imaging. Written informed consent will be obtained;

Exclusion Criteria

History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen vascular diseases, Other autoimmune diseases, Malignancies, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, hematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease).

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Active lesion in MRI imaging. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: imaging by MRI method.

Secondary Outcome Measures

Name	Time	Method
Serum level of AST. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.;Serum level of uric acid. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.;Serum level of ALT. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.;Serum level of BUN. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.